Fexofenadine Hydrochloride 30mg Oral Suspension For pharmaceutical companies developing liquid dosage-form portfolio, formulation data can be used for product development. Fexofenadine Hydrochloride 30mg Oral Suspension liquid pharmaceutical formulation of Fexofenadine Hydrochloride with a specification of 30mg in the finished dosage form. The liquid pharmaceutical formulation has to be formulated with particle size, dispersion, viscosity, sedimentation, dispersibility, and dose uniformity considerations and with the presiding suspending agent, excipient, sugar, flavor, stabilizer, and the other pharmaceutical excipients.
The product development of Fexofenadine Hydrochloride 30mg Oral Suspension is considered at the active pharmaceutical ingredient stage and its compatibility with the intended suspension vehicles. Critical properties are identified such as particle size, surface property, particle density, moisture uptake and dispersion profile.
A suspension base should be formulated to keep the active ingredient evenly distributed throughout the liquid vehicle during storage and normal handling. Depending on the formulation, the excipient system may include suspending agents, wetting agents, viscosity-inducing agents, sweetening agents, flavoring agents, buffers, stabilizers and preservatives as indicated.
These excipients are typically present as a combination at a defined concentration determined by formulation development studies, with the aim of providing an optimum viscosity (not to an extent that the preparation becomes too gel-like) and also allowing for sedimentation and redispersion.
Some compatibilities of Fexofenadine Hydrochloride with the filler and granulating agents can be checked and studied from the parameters like pH, Viscosity, Particle size distribution, and physical appearance in pre formulation.
Particle-Size Management Particle size management plays a crucial role in the process of manufacturing Fexofenadine Hydrochloride 30mg Oral Suspension. Changes in the particle size can affect the rate of settling, sediment volume, dispersibility and physical stability of the suspension.
The active may be milled or sieved, as appropriate, on the requirements of the approved raw-material specification. The material is checked for conformity before it is added to the formulation.
4. Aids in mixing Wetting agents may be added, when necessary, to promote good contact of the active particles with the liquid vehicle. Effective wetting is crucial for avoiding floating, caking or agglomeration during preparation.
The suspension system can be pre-pared in a separate vessel or added into the main manufacturing vessel as per validated process. Some suspending agents may need controlled dispersion or hydration before addition of the active ingredient.
Fexofenadine Hydrochloride is then blended with agitation. It is important that the order of addition, impeller speed, mixing time, and batch temperature are carefully monitored so that the dispersion results are repeatable within specified process limits.
Representative bulk samples can be taken from a variety of locations to test for consistency prior to packing.
The finished product manufacturing process starts with the identification, dispensation and testing of all of the approved raw materials. The vehicle for the liquid is then compounded based on the master manufacturing instructions, followed by the dissolution of soluble excipients.
The suspending system is then formulated following the formulation procedure. To ensure a more uniform distribution, the active material is slowly added to the mixture during constant agitation.
The homogenization process may be used to enhance uniformity of distribution of particles and reduce localized variations, depending on the formulation design. Processing conditions should be carefully controlled to retain the original particles properties and viscosity of the product.
During bulk manufacture, parameters such as pH, temperature, speed of mixing, time of mixing and viscosity are all recorded. In-process testing can take place at pre-determined points to check that the formulation remains within specification.
The bulk is then subjected to any appropriate screening or filtration if suitable for the suspension formulation. Care is taken not to include any such processing steps which may exclude or change the dispersed active ingredient.
Following bulk processing, the suspension is transferred to the filling operation by a controlled and programmed process to avoid settling or segregation during transfer.
6 Testing Fexofenadine Hydrochloride 30mg Oral Suspension 6.1 Identification and assay of Fexofenadine Hydrochloride may be determined by appropriate validated procedures. Physical-performance tests on the oral suspension.
The formulation of the product is a suspension; since this is a dispersed system, it is important that the dispersed phase should be uniform. Tests could be sedimentation volume, redispersion, viscosity, particle-size distribution, and suspension homogeneity in accordance with a set specification.
The physical characteristics of the suspension should be reproducible within a manufacturing batch. Procedures for sampling should consider the chance of settling during manufacture, transfer, storage and testing.
Additional finished-product specifications could include appearance, color, odor, pH, specific gravity, fill volume, and microbial-quality control and maintenance. Aqueous oral suspension could also require formulating microbial-quality control and preservation policy as an aspect of its development program.
The dispensing container should permit reliable withdrawal of product. If appropriate, the performance of the container and closure can be assessed for fill-volume consistency, protection against leakage and compatibility with the formulation.
All finished-product test results should be recorded and evaluated using normal quality-control practices.
Stability studies are conducted on Fexofenadine Hydrochloride 30mg Oral Suspension to show that it maintains the required physical and chemical properties during the storage period.
Samples for stability testing can be tested for assay, degradation products, appearance, pH, viscosity, sedimentation, redispersion, particle characteristics, microbiological quality, etc.
Suspension formulations need special attention for physical stability. Sedimentation rate alteration, formation of a compact sediment or risibility of the sediment may suggest changes in the suspension system and therefore should be studied for stability.
Working with the packaging development process, pharmaceutical-grade bottles and appropriate closures can be chosen. Compatibility testing may be conducted on the formulation with the packaging to examine the risk of interaction; integrity tests on the closure could provide evidence of protection from leakage and compromise.
The finished pack should be suitable for transportation and storage but convenient for handling. The labels should bear the approved name of the suspension, ingredients, strength, batch details, manufacturer's details, expiry date, storage condition, and other legal requirements.
The stability data obtained during development may be used to establish shelf life and storage requirements.
Fexofenadine Hydrochloride 30mg Oral Suspension in the Sydenham's PCD Pharma Franchise Range Standard controlled formulation development, manufacturing and documented quality procedures allow Fexofenadine Hydrochloride 30mg Oral Suspension to be added to a mixed liquid medicine portfolio. Clear specifications for Sydenham's PCD Pharma Franchise will assist to provide Product Development, Packaging and Distribution consistency.
A full product-development file can comprise raw-material specifications, supplier approval data, formula and composition, batch manufacturing instructions, in-process control parameters, analytical methods, finished-product specifications, packaging specifications, and stability protocols.
Pay attention to the suspension uniformity as the active ingredient is a dispersed phase in the liquid system. Proper particle-size control, wetting, and choice of suspending agents, combined with optimized mixing and dispersibility testing, can achieve reproducibility of the quality of the product.
Quality should encompass components such as incoming raw-material inspection, bulk preparation, homogenization, filling, capping, labeling, and packaging, to final batch release. Good batch records ensure traceability for each lot manufactured.
Information for Product Portfolio Management Product mix, and technical information should all be aligned within product catalogs, packaging artwork, digital product listings and other business collateral.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech